Immunologic responses to antifibrotic treatment in IPF patients.
Sign Up to like & getrecommendations! Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.107525
Abstract: BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease limited to the lungs. Immunological dysregulation may significantly participate in the pathophysiology of IPF. The immunological responses to nintedanib therapy in IPF patients… read more here.
Keywords: antifibrotic treatment; treatment ipf; cell percentages; ipf patients ... See more keywords
Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis.
Sign Up to like & getrecommendations! Published in 2022 at "Respiratory medicine"
DOI: 10.2139/ssrn.4184350
Abstract: INTRODUCTION Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease for which two effective antifibrotics, nintedanib and pirfenidone, are available. However, many patients receive a reduced dosage or pause treatment due to side effects… read more here.
Keywords: idiopathic pulmonary; nintedanib pirfenidone; antifibrotic treatment; reduction ... See more keywords